Drug intelligence / Profile preview

AZX1101

Development stage: Discontinued
Lead developer: GridAI Technologies
Modality: Recombinant Proteins and Enzymes
Administration: Oral

Overview

**AZX1101** is an oral, locally acting recombinant beta-lactamase enzyme preparation of bacterial origin originally developed by AzurRx for protection of the gastrointestinal microbiome during treatment with intravenous beta-lactam antibiotics. It is intended to enzymatically inactivate antibiotic molecules that enter the intestinal tract, thereby limiting antibiotic-mediated disruption of commensal gut flora and potentially reducing antibiotic-associated diarrhea, *Clostridioides difficile* infection, and selection of resistant bacteria. The program remained preclinical and is no longer listed as an active development program. ([ae.marketscreener.com](https://ae.marketscreener.com/quote/stock/GRIDAI-TECHNOLOGIES-CORP-30506551/news/AzurRx-BioPharma-Announces-Publication-of-U-S-Patent-Application-for-AZX1101-25697946/))

Beyond the preview

Go deeper on AZX1101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AZX1101.